Teva Pharmaceutical Industries CEO Says Just-Launched Schizophrenia Drug Weltruza Won't See Significant Revenue Until Second Half Of 2027, In Good Position For 2028; Despite Growth In Branded Drugs, Generics To Continue To Grow And Be Profitable Due To Biosimilars Pipeline; Co. Aims To Grow In 2027 Despite U.S. Inflation Reduction Act Impact On Its Austedo Drug
-Conference Call.
Share
Why It Matters
Teva just launched a new schizophrenia medicine called Weltruza. It won't make much money until late 2027, but the company thinks it can still grow in 2026 and 2027 overall.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.